Cinobufagin suppresses colorectal cancer growth via STAT3 pathway inhibition.
Ying Bai, Xuye Wang, Mengsi Cai, Chunbo Ma, Youqun Xiang, Wanle Hu, Bin Zhou, Chengguang Zhao, Xuanxuan Dai, Xiaokun Li, Haiyang Zhao
Abstract
. Mechanistically, cinobufagin simultaneously suppressed the phosphorylation of signal transducer and activator of transcription 3 (STAT3) and blocked the interleukin-6 (IL6)-induced nuclear translocation of STAT3. IL6 activated the STAT3 pathway, subsequently inducing epithelial-mesenchymal transition (EMT). Furthermore, cinobufagin suppressed EMT in CRC by inhibiting the STAT3 pathway. Animal experiments clearly showed that cinobufagin could reduce tumor growth. Cinobufagin may be used clinically as a novel STAT3 inhibitor for CRC adjuvant therapy.
Topics & Concepts
STAT3STAT proteinCancer researchColorectal cancerApoptosisIn vivoCell growthActivator (genetics)Growth inhibitionChemistryBiologyCancerMedicineInternal medicineBiochemistryReceptorBiotechnologyCytokine Signaling Pathways and InteractionsBioactive Compounds and Antitumor AgentsErythrocyte Function and Pathophysiology